Ichnos Glenmark Innovation subsidiary IGI Therapeutics has signed an exclusive licensing agreement with AbbVie for ISB 2001, ...

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

FDA designates MB-101 CAR T-cell therapy for glioblastoma, highlighting its potential in treating aggressive brain tumors ...

The deal hands AbbVie a drug that’s shown early promise in multiple myeloma and may be useful treating other cancers and ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Preclinical data support a novel combination of MB-101 (IL13Ra2-targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus) to optimize clinical results FDA previously granted Orphan Drug ...

The study aims to uncover the immunological basis of Tanshi (phlegm-dampness) constitution—a subhealth type in traditional Chinese medicine ...

Glenmark Pharmaceuticals' shares surged 10% to an all-time high of ₹2,094 following the announcement of an exclusive ...

Glenmark Pharma share price today: Shares of Glenmark Pharma surged 10 per cent, recording a 52-week high of ₹2,094.40 on ...

The antibody, ISB 2001, is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) ...

The FDA granted orphan drug designation to a CAR T-cell therapy for recurrent glioblastoma and high-grade astrocytomas.

AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase ...